Subscribe“Ubiquitin” is the apt term for a molecule that plays a vital role in every cell in our body. Associate Professor Michael Rape, winner of a 2012 Bakar Fellowship, is now on the trail of a potential drug to interrupt excessive ubiquitin production and prevent uncontrolled cell division, a hallmark of cancer.
Tag: cancer
Bakar Fellows Program: Probing the cell's 'everywhere' molecule
April 10, 2013:
Howard Hughes Medical Institute names three new campus investigators
May 9, 2013:
Three young faculty members – Nicole King, Michael Rape & Russell Vance – have won the most sought-after appointment for a researcher at any American university: as a Howard Hughes Medical Institute investigator. The institute will pay their salaries in the Department of Molecular & Cell Biology and provide research funding, freeing them from constant application for federal research grants.
New details on the molecular machinery of cancer
February 15, 2013:
Chemist Jay Groves and colleagues at Berkeley Lab have used cutting-edge tools to reveal the workings of the epidermal growth factor receptor, which is screwed up in numerous cancers. Their picture of how the receptor changes structure when activated could help scientists understand other cancer triggers.
Check box on state tax return and help fund UC cancer research
February 15, 2013:
File your California tax return and join the fight against cancer! By checking a box, the public can direct some of their tax payment to the California Breast Cancer Research Fund and the California Cancer Research Fund. Both are administered by UC for research on the diagnosis and treatment of all cancers and dissemination of information about cancer prevention and early diagnosis.
To revert breast cancer cells, give them the squeeze
December 17, 2012:
UC Berkeley researchers have found that compression can guide malignant breast cells back to a normal growth pattern. The findings, presented at the American Society for Cell Biology meeting, demonstrate the influence of mechanical forces on a cell’s destiny.
Statins may stem tumor growth, new study finds
September 3, 2012:
Researchers at ETH Zurich in Switzerland and UC Berkeley have found that statins, widely prescribed to help lower cholesterol, can inhibit the growth of lymphatic vessels. The effect was detected by Michael Detmar, professor at ETH Zurich, and Lu Chen, UC Berkeley assistant professor of vision science and optometry. Chen, a leading expert in corneal lymphatic research, showed that a compound found in statins significantly suppressed lymphatic vessel growth in the cornea, an ideal and widely used tissue for lymphatic examination.
Lois Swirsky Gold, expert on toxins and carcinogens, dies at 70
June 13, 2012:
Lois Swirsky Gold, a political scientist who became a self-taught expert on the toxic and carcinogenic effects of chemicals, died May 16 at California Pacific Medical Center in San Francisco, Calif., after a brief battle with cancer. Gold, a resident of Oakland and a UC Berkeley researcher, was 70.
Q&A: Carolyn Bertozzi on her love affair with sugar biology
October 18, 2011:
Newly elected to the Institute of Medicine, chemistry professor Carolyn Bertozzi answers questions about her research and teaching and the creative atmosphere at UC Berkeley.
Using religion to address health needs in underserved communities
February 18, 2011:
In Alameda Country, researchers from the School of Public Health and Kaiser Permanente are reaching out, through local churches, to offer health screening and education to two groups — African Americans and Afghan refugee women.
Fighting cancer across the disciplines
February 18, 2011:
Berkeley biophysicist Jan Liphardt, director of the new Bay Area Physical Sciences-Oncology Center, believes that a new, multidisciplinary approach to understanding fundamental aspects of cancer is key to making progress in the ongoing war against the disease.
Preventing cells from getting the kinks out of DNA
May 20, 2010:
A new discovery by UC Berkeley biochemists could pave the way for new research into how to re-design some of the standard antibiotic and anti-cancer drugs to make them more effective poisons for cancer cells and harmful bacteria.
